Investment Firm Discloses Stake in MDS, Suggests Spin-Off | GenomeWeb
NEW YORK (GenomeWeb News) – Investment firm Obrem Capital Management disclosed in a filing with the US Securities and Exchange Commission yesterday that it has purchased roughly 6.2 million shares of MDS’ common stock and now owns a 5.1 percent stake in the company.
 
Obrem and its affiliates have been accumulating shares in the Mississauga, Ontario-based firm since late February.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.